Henry Schein (NASDAQ:HSIC) CEO Thomas Popeck Sells 1,355 Shares

Henry Schein, Inc. (NASDAQ:HSIC) CEO Thomas Popeck sold 1,355 shares of Henry Schein stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the transaction, the chief executive officer directly owned 86,182 shares of the company’s stock, valued at $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Henry Schein Trading Down 0.6%

Henry Schein stock traded down $0.44 during mid-day trading on Friday, hitting $72.24. The company’s stock had a trading volume of 1,313,906 shares, compared to its average volume of 1,693,865. The stock has a market cap of $8.29 billion, a PE ratio of 22.09, a P/E/G ratio of 2.15 and a beta of 0.88. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $89.29. The company has a 50 day moving average of $77.72 and a 200-day moving average of $72.98. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period last year, the business posted $1.19 EPS. Henry Schein’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS estimate to $1.62 from $1.44, signaling stronger expected back‑half performance for FY2027. Zacks note
• Positive Sentiment: Zacks boosted its Q3 2027 EPS to $1.49 from $1.42 and lifted FY2027 to $5.76 from $5.68, implying improved full‑year outlook beyond FY2026. Zacks note
• Positive Sentiment: Zacks nudged FY2026 guidance upward to $5.26 from $5.23 and raised Q3 2026 to $1.43 (from $1.39) and Q4 2026 to $1.44 (from $1.43), reflecting incremental improvement to near‑term full‑year estimates. Zacks note
• Neutral Sentiment: Zacks published an FY2028 EPS projection of $6.28 (new/forward‑looking estimate). This provides a growth runway but is not a direct revision to consensus today. Zacks note
• Negative Sentiment: Zacks cut its Q2 2027 EPS forecast to $1.38 from $1.47, a notable downgrade for the mid‑year quarter that may pressure near‑term expectations. Zacks note
• Negative Sentiment: Zacks trimmed Q1 2027 to $1.28 from $1.35 and lowered Q1 2026 to $1.20 from $1.22, indicating weaker near‑term quarterly visibility. Zacks note

Institutional Trading of Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of HSIC. Ameriprise Financial Inc. boosted its holdings in shares of Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Bank of Montreal Can lifted its position in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the last quarter. Norges Bank acquired a new position in Henry Schein in the second quarter valued at $89,476,000. M.D. Sass LLC purchased a new position in shares of Henry Schein during the second quarter worth about $79,201,000. Finally, Schroder Investment Management Group grew its holdings in shares of Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after purchasing an additional 936,471 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HSIC. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wells Fargo & Company boosted their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen cut Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. JPMorgan Chase & Co. raised their price target on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley upped their target price on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.